4.1 Review

Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders

Journal

EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 10, Issue 8, Pages 1347-1359

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.93

Keywords

cognitive-behavioral therapy; early intervention; olanzapine; omega-3 fatty acids; prodrome; psychosis; risperidone; ultra-high risk; ziprasidone

Funding

  1. National Institute of Mental Health
  2. Pfizer

Ask authors/readers for more resources

During recent decades, interest in the prevention of mental illnesses has increased. Improved diagnostic tools, the advent of atypical antipsychotic medications and the development of phase-specific psychosocial treatments have made intervention research in people at ultra-high risk for developing schizophrenia or a related psychotic disorder possible. Preliminary data suggest that low doses of atypical antipsychotic medications augmented by psychosocial treatments may delay the onset of psychosis in some individuals. Findings support further research for the establishment of best-practice standards.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available